-
Mashup Score: 0
Intermediate-risk thyroid cancer accounts for up to two-thirds of all cases of differentiated thyroid cancer (DTC), yet it is subject to substantial variations in risk stratification and management strategies.
Source: www.endocrinepractice.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0
In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported. Agnes Gasiorek, PhD, MSc Pharm, senior clinical pharmacology specialist at Novo Nordisk, presented the findings of the first-in-human study of amycretin (Novo Nordisk), a unimolecular
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💊An novel oral amylin and GLP-1 receptor coagonist from @novonordisk induced up to 13.1% weight loss at 12 weeks and had no significant safety issues for adults with #obesity in a phase 1 trial. Read more from this @EASDnews talk ⬇️ #EASD2024 https://t.co/hkRlQqquZK
-
-
Mashup Score: 0AACE Committee Descriptions - 3 hour(s) ago
View the most current descriptions and charges for AACE committees.
Source: pro.aace.comCategories: General Medicine News, EndocrinologyTweet-
We're seeking volunteers to serve on two new subcommittees: the Certificate Programs Subcommittee and the Exploratory Certification Subcommittee! Learn more: https://t.co/rWvBrzaMpH #endotwitter #WeAreAACE https://t.co/WiPpUPHCKJ
-
-
Mashup Score: 0Endocrine-Disrupting Chemicals SIG - 3 hour(s) ago
Hear from colleagues on the impact of endocrine disrupting chemicals and the latest on how we can overcome them.
Source: www.endocrine.orgCategories: General Medicine News, EndocrinologyTweet-
How to Conduct Systematic Reviews and Meta-Analyses Webinar | Join our team on October 3 at 11:00 AM ET where the EDC SIG will inaugurate the working groups’ activity by providing methodological concepts and a practical implementation approach: https://t.co/ak3TjZZuOX #EDCs https://t.co/mGZY9Zkk9L
-
-
Mashup Score: 2Keep Your Kidneys Healthy - 3 hour(s) ago
The number one cause of kidney disease is diabetes. Understanding this connection is the first step to helping avoid kidney problems.
Source: diabetes.orgCategories: General Medicine News, EndocrinologyTweet-
Living with diabetes increases your risk for developing chronic kidney disease (CKD). Learn about the causes and risks and find answers to common questions đź’¬ at https://t.co/etzgcs0pKl. @DaVita https://t.co/DbN4YcjyFe
-
-
Mashup Score: 0National Scientific & Health Care Achievement Awards | American Diabetes Association - 3 hour(s) ago
Presented to recognize and honor individuals in the diabetes scientific and medical community, the American Diabetes Association’s National Scientific & Health Care Achievement Awards recognized individuals who have demonstrated exceptional leadership. Specifically, these awards honor those individuals who have made si gnificant contributions through their outstanding career achievements and support in the areas of diabetes research, clinical care and education including training, mentoring and internation
Source: professional.diabetes.orgCategories: General Medicine News, EndocrinologyTweet-
Nominate deserving individuals for the @AmDiabetesAssn 2025 National Scientific & Health Care Achievement Awards! Recognize those who've made significant strides in diabetes care and research. Submit your nominations by Sept 20, 2024: https://t.co/lPAwR2w2IB https://t.co/L9w2qCLo4v
-
-
Mashup Score: 2INNOVATIVE SCIENCE TO TRANSFORMATIONAL CARE - 4 hour(s) ago
The preeminent international conference for obesity researchers and clinicians, ObesityWeek® is home to the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy. Overcoming obesity requires multi-disciplinary approaches. This is the conference that encompasses the full spectrum of obesity science: from basic science research, to translational research and clinical application, to public policy; from diet, exercise, lifestyle, and psychology to medical and surgical interventions; from pediatric to geriatric to underserved populations. ObesityWeek® 2024 will be held November 2-6 in San Antonio, Texas. Registration and housing open in May.
Source: obesityweek.orgCategories: General Medicine News, EndocrinologyTweet-
Pediatric obesity medicine providers can participate in sessions and symposia focused on their profession at this year’s ObesityWeek®. View the interactive schedule on the ObesityWeek® website at https://t.co/mibEiAvab0
-
-
Mashup Score: 0
Join us as the American Diabetes Association®’s Amputation Prevention Alliance presents a special event! Tune in to gain expert insights into preventing diab…
Source: www.youtube.comCategories: General Medicine News, EndocrinologyTweet-
Encourage the people and patients you see living with diabetes to watch this insightful event by the ADA's Amputation Prevention Alliance! 🌟 They will learn from experts about preventing diabetic foot ulcers and recognizing early signs. 👣 Tune in now at https://t.co/ZtzMo7y3DJ. https://t.co/TaG3zuAsSS
-
-
Mashup Score: 9Resources - 4 hour(s) ago
A selection of campaign materials, assets and factsheets is available to download for free. Remember to read our terms of use before making use of World Obesity Day campaign
Source: www.worldobesityday.orgCategories: General Medicine News, EndocrinologyTweet-
Our latest #WorldObesityAtlas 2024, released for #WorldObesityDay â•ď¸Ź, is available now! 📢 It's clear that governments around the world must do more to tackle unhealthy and unsustainable environments. ❗️ ➡️ Find out more in our #Atlas2024: https://t.co/75yaFzLwxg #WOD2024 https://t.co/ddKECwogEP
-
-
Mashup Score: 0
SGLT2 inhibitors did not significantly increase days free of organ support or reduce mortality in patients hospitalised with COVID-19. SGLT2 inhibitors were well tolerated with no observed safety concerns. Overall, these findings do not support the use of SGLT2 inhibitors as standard care in patients hospitalised with COVID-19.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for #COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial https://t.co/lJtMJxcCYR #SGLT2 inhibitors #COVID19
-
This review underscores the need for personalized treatment decisions guided by comprehensive risk assessment and patient-centered care. Read more: https://t.co/cZkq5Cnp4v @Els_ENDO @vtangpricha #endocrinology